Tango Therapeutics, Inc. announced that on January 7, 2026, Barbara Weber, M.D. notified the board of directors of the Company of her retirement and resignation as President effective as of January 8, 2026. On January 8, 2026, Malte Peters, M.D., a member of the Board, was appointed as the Company?s President. Dr. Weber, the company?s founding CEO, will become Executive Chair for 2026 and then serve as non-executive chair starting in 2027.
In her new capacity as Executive Chair, Dr. Weber will remain closely involved with the senior management team of Tango, supporting the company?s strategic priorities and working with Dr. Peters to ensure a seamless transition and continued clinical execution throughout 2026. Alexis Borisy, the current Board Chair, will transition to Lead Independent Director. An accomplished industry veteran, Dr. Peters joins the Tango executive team with a proven track record in both early- and late-stage clinical development, having led global teams and brought innovative therapies to patients.
In addition to his service on the Tango board, he was Chief Research and Development Officer at MorphoSys AG, following his tenure as Chief Development Officer and board member since March 2017, where he oversaw a large development organization and the global regulatory approval of Monjuvi in combination with lenalidomide in diffuse large B cell lymphoma. Earlier in his career, he was Global Head of Clinical Development for the Biopharmaceuticals Business Unit at Sandoz International. He also held key leadership positions at Novartis as Clinical Head and Site Head for Basel and East Hanover in Oncology Translational Medicine.
Dr. Peters earned his medical degree from the Freie Universität Berlin, Germany, with medical training at the Universities of Padova, Italy, and Bochum and Berlin, Germany.
